Braveheart Investments Regulatory News (BRH)

19 July 2016

Braveheart Investment Group plc

('Braveheart', the 'Company')

AGM Statement

Braveheart Investment Group plc (AIM: BRH), the venture fund manager and investor, will hold its Annual General Meeting in London later today.

The Company's AGM statement, from Braveheart Chairman Jeremy Delmar-Morgan, is as follows:

"I am pleased to report that we have made a positive start to the year, achieving modest profitability during the first quarter ended 31st June 2016 and that we are on track to generate profits during the full year ending 31st March 2017.

"We have now commenced the implementation of our new direct investment strategy with investments in Paraytec, a UK company producing scientific instruments used for the analysis of fluids and particles in drug development, and Kirkstall, a UK company producing flow chamber systems used in the laboratory testing of drugs on living cells and tissue culture.

"Having completed the Group's re-organisation and cost saving program we are now firmly focused on growing and developing group businesses by deploying our capital, and submitting bids for the management of new venture capital funds with the aim of generating positive shareholder returns."

Further information: